Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

PHARMACIE KERANGAL : revenue, balance sheet and financial ratios

PHARMACIE KERANGAL is a French company founded 13 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in RENNES (35200), this company of category PME shows in 2016 a revenue of 2.6 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-02

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - PHARMACIE KERANGAL (SIREN 789095163)
Indicator 2024 2023 2022 2021 2019 2018 2017 2016
Revenue N/C N/C N/C N/C N/C N/C N/C 2 599 746 €
Net income 159 646 € 239 798 € 142 710 € 184 604 € 121 918 € 120 728 € 186 944 € 122 720 €
EBITDA N/C N/C N/C N/C N/C N/C N/C 259 754 €
Net margin N/C N/C N/C N/C N/C N/C N/C 4.7%

Revenue and income statement

In 2024, PHARMACIE KERANGAL generates positive net income of 160 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2024: 123 k€ -> 160 k€.

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

159 646 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 110%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 41%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

110.499%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

41.345%

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

21.8%

Solvency indicators evolution
PHARMACIE KERANGAL

Sector positioning

Debt ratio
110.5 2024
2022
2023
2024
Q1: 16.46
Med: 58.47
Q3: 154.89
Average +15 pts over 3 years

In 2024, the debt ratio of PHARMACIE KERANGAL (110.50) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
41.34% 2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Average -18 pts over 3 years

In 2024, the financial autonomy of PHARMACIE KERANGAL (41.3%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 202.94. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

202.941

Liquidity indicators evolution
PHARMACIE KERANGAL

Sector positioning

Liquidity ratio
202.94 2024
2022
2023
2024
Q1: 129.47
Med: 182.13
Q3: 260.78
Good +11 pts over 3 years

In 2024, the liquidity ratio of PHARMACIE KERANGAL (202.94) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 179 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 479 days. Excellent situation: suppliers finance 300 days of the operating cycle (retail model).

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

179 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

479 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
PHARMACIE KERANGAL

Positioning of PHARMACIE KERANGAL in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 225 transactions of similar company sales in 2024, the value of PHARMACIE KERANGAL is estimated at 2 228 776 € (range 1 552 084€ - 3 334 376€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
225 transactions
1552k€ 2228k€ 3334k€
2 228 776 € Range: 1 552 084€ - 3 334 376€
NAF 5 année 2024

Valuation method used

Net Income Multiple
159 646 € × 14.0x = 2 228 776 €
Range: 1 552 084€ - 3 334 377€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare PHARMACIE KERANGAL with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about PHARMACIE KERANGAL

What is the revenue of PHARMACIE KERANGAL ?

The revenue of PHARMACIE KERANGAL in 2016 is 2.6 M€.

Is PHARMACIE KERANGAL profitable?

Yes, PHARMACIE KERANGAL generated a net profit of 160 k€ in 2024.

Where is the headquarters of PHARMACIE KERANGAL ?

The headquarters of PHARMACIE KERANGAL is located in RENNES (35200), in the department Ille-et-Vilaine.

Where to find the tax return of PHARMACIE KERANGAL ?

The tax return of PHARMACIE KERANGAL is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does PHARMACIE KERANGAL operate?

PHARMACIE KERANGAL operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.